South Korea · Delayed Price · Currency is KRW Neuromeka Statistics
Total Valuation
Neuromeka has a market cap or net worth of KRW 334.30 billion. The enterprise value is 370.64 billion.
| Market Cap | 334.30B |
| Enterprise Value | 370.64B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Neuromeka has 18.61 million shares outstanding. The number of shares has increased by 9.16% in one year.
| Current Share Class | 18.61M |
| Shares Outstanding | 18.61M |
| Shares Change (YoY) | +9.16% |
| Shares Change (QoQ) | +1.76% |
| Owned by Insiders (%) | 30.35% |
| Owned by Institutions (%) | 17.89% |
| Float | 12.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.41 |
| PB Ratio | 9.01 |
| P/TBV Ratio | 9.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 20.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.73, with a Debt / Equity ratio of 1.32.
| Current Ratio | 0.73 |
| Quick Ratio | 0.40 |
| Debt / Equity | 1.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.06 |
| Interest Coverage | -4.21 |
Financial Efficiency
Return on equity (ROE) is -145.44% and return on invested capital (ROIC) is -12.66%.
| Return on Equity (ROE) | -145.44% |
| Return on Assets (ROA) | -10.89% |
| Return on Invested Capital (ROIC) | -12.66% |
| Return on Capital Employed (ROCE) | -34.65% |
| Weighted Average Cost of Capital (WACC) | 15.29% |
| Revenue Per Employee | 147.61M |
| Profits Per Employee | -326.47M |
| Employee Count | 123 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 1.54 |
Taxes
In the past 12 months, Neuromeka has paid 66.31 million in taxes.
| Income Tax | 66.31M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +7.18% in the last 52 weeks. The beta is 2.25, so Neuromeka's price volatility has been higher than the market average.
| Beta (5Y) | 2.25 |
| 52-Week Price Change | +7.18% |
| 50-Day Moving Average | 19,181.87 |
| 200-Day Moving Average | 33,672.30 |
| Relative Strength Index (RSI) | 47.74 |
| Average Volume (20 Days) | 342,528 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Neuromeka had revenue of KRW 18.16 billion and -40.16 billion in losses. Loss per share was -2,264.87.
| Revenue | 18.16B |
| Gross Profit | 3.34B |
| Operating Income | -16.26B |
| Pretax Income | -40.26B |
| Net Income | -40.16B |
| EBITDA | -13.24B |
| EBIT | -16.26B |
| Loss Per Share | -2,264.87 |
Balance Sheet
The company has 13.40 billion in cash and 49.02 billion in debt, with a net cash position of -35.61 billion or -1,913.18 per share.
| Cash & Cash Equivalents | 13.40B |
| Total Debt | 49.02B |
| Net Cash | -35.61B |
| Net Cash Per Share | -1,913.18 |
| Equity (Book Value) | 37.11B |
| Book Value Per Share | 1,954.72 |
| Working Capital | -12.24B |
Cash Flow
In the last 12 months, operating cash flow was -18.56 billion and capital expenditures -5.26 billion, giving a free cash flow of -23.82 billion.
| Operating Cash Flow | -18.56B |
| Capital Expenditures | -5.26B |
| Depreciation & Amortization | 3.02B |
| Net Borrowing | 14.17B |
| Free Cash Flow | -23.82B |
| FCF Per Share | -1,279.67 |
Margins
Gross margin is 18.37%, with operating and profit margins of -89.54% and -221.17%.
| Gross Margin | 18.37% |
| Operating Margin | -89.54% |
| Pretax Margin | -221.73% |
| Profit Margin | -221.17% |
| EBITDA Margin | -72.92% |
| EBIT Margin | -89.54% |
| FCF Margin | n/a |
Dividends & Yields
Neuromeka does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.16% |
| Shareholder Yield | -9.16% |
| Earnings Yield | -12.01% |
| FCF Yield | -7.13% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 5, 2026. It was a forward split with a ratio of 1.5.
| Last Split Date | Aug 5, 2026 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
Neuromeka has an Altman Z-Score of 3.91 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.91 |
| Piotroski F-Score | 3 |